The Rare Tumors program is committed to providing exceptional care for children with uncommon cancerous conditions, such as germ-cell tumors, retinoblastoma and colorectal cancer. We offer the latest therapies and clinical trials and provide access to pediatric experts with extensive experience treating children with rare cancers.
Certain types of childhood cancer are very uncommon. At Dana-Farber/Boston Children's Cancer and Blood Disorders Center, we are committed to providing exceptional care for children with rare cancerous conditions, such as germ-cell tumors, retinoblastoma and colorectal cancer.
Our Rare Tumors Program offers the latest therapies and clinical trials and provides access to pediatric experts with extensive experience treating children with rare cancers. Your child will be treated by some of the world's most experienced pediatric oncologists at Dana-Farber Cancer Institute and internationally recognized pediatric subspecialists at Boston Children's Hospital.
Your child's core care team includes pediatric oncologists, radiotherapists, surgeons, pathologists, radiologists, nurses, and psychosocial and physical therapy specialists, among many others.
We are New England's Phase I referral center for the Children's Oncology Group, enabling us to offer clinical trials unavailable at other regional centers.
Our director, Carlos Rodriguez-Galindo, MD, is chair of the Boston Children's Hospital Oncology Group Rare Tumors Committee.
We provide long-term treatment and childhood cancer survivor support through Dana-Farber's David B. Perini, Jr. Quality of Life Clinic.
We treat children with the following conditions:
Our physicians are focused on family-centered care: From your first visit, you'll work with a team of professionals who are committed to supporting all of your family's physical and psychosocial needs.
Through Dana-Farber/Boston Children's, a 60-year partnership between Dana-Farber Cancer Institute and Boston Children's Hospital, children receive individualized care to treat every aspect of their condition from an expert team of subspecialists, including:
Other pediatric care providers, including other subspecialists, nutritionists, physical and occupational therapists, psychologists and social workers, are available for consultation, whenever they are needed.
We consider you and your child integral parts of the care team and not simply recipients of care. You and your team will work together to customize a plan of care for your child.
Children treated in the Rare Tumors Program benefit from the work of our experienced basic, translational and clinical researchers, who study the scientific causes of rare cancers to discover new treatment options.
Like all patients who were treated with chemotherapy and/or radiation, survivors of rare tumors may be at risk of developing health problems later in life.
To help patients monitor their overall health after treatment is completed, we encourage children and adolescents to continue long-term care through Dana-Farber's David B. Perini Jr. Quality of Life Clinic.
Our staff of compassionate specialists includes pediatric oncologists, surgeons, radiation oncologists, radiologists and ophthalmologists. Our physicians are focused on family-centered care. From your first visit, you'll work with a team of professionals who are committed to supporting all of your family's physical and psychosocial needs.
Dana-Farber/Boston Children's is a world leader in opening new avenues of translational research, bringing laboratory advances to the bedside and doctor's office as quickly as possible. All senior medical staff members of the Rare Cancers Program participate in clinical research activities.
The main objective of our research program is to improve the understanding and treatment of rare cancers and develop new ways to treat children with these conditions.
Dana-Farber/Boston Children's is the New England Phase I Center of the Children's Oncology Group.
The Children's Oncology Group is a consortium of cancer treatment centers across the United States, Canada, and other countries, that conduct studies of pediatric cancers. Our participation in the Children's Oncology Group gives children with rare tumors unparalleled access to the newest clinical trials.
Children with progressive or recurrent tumors may be eligible for experimental therapies through these groups, or through one of our independent clinical investigators.
The long-term outcome for children with rare cancerous tumors depends on a variety of factors, including the type of tumor and whether the disease has spread (metastasized) by the time the child is diagnosis. Our research continues to help us understand the causes of cancer so we can develop more targeted, effective therapies.
Referring physicians: 617-632-5508 or 1-888-Pedi-Onc (733-4662)
We understand a cancer diagnosis is extremely difficult to cope with. We are available to offer a consultation or second opinion for your child.
If your child has been diagnosed with Hodgkin lymphoma, please contact our program at 888-PEDI-ONC (888-733-4662).
To help us conduct a precise evaluation, it's important we receive a full summary of your child's initial diagnosis. This includes any laboratory or pathology reports, any x-ray, radiographic or MRI images and a list of any previous treatments your child may have received. Please have as much of the following information gathered as possible when you call or bring it with you to your appointment:
Boston Children's Hospital300 Longwood AvenueBoston, MA 02115
Dana-Farber Cancer Institute450 Brookline AvenueBoston, MA 02215
Browse clinical trials
Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215 | Call us toll-free:
(866) 408-DFCI (3324)